NCT07143734RecruitingPhase 2
Transcranial Pulse Stimulation for Alzheimer's Disease
A Pilot Randomized Placebo-Controlled Trial of Transcranial Pulse Stimulation (TPS) in Early Alzheimer's Disease (AD) Subjects
Source: ClinicalTrials.gov · Last updated 16 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 21 Jul 2025
- Primary completion date
- Apr 2026
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Alzheimer disease
- NCT number
- NCT07143734
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- From 21 Jul 2025 to the primary completion date, Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of any metal implants in the brain
Other illness
- Major neurological conditions, including:
- Hemophilia or other blood clotting disorders
- History of thrombosis
Other
- Cannot understand Chinese.
- Mentally incapacitated, unable to provide informed consent
- Inability to remain still for 30 minutes
- Lack of available family caregiver to answer questionnaires
- Alcohol or substance dependence
- Brain tumor
- Brain aneurysm
Who the study is looking for
- Adults who have been clinically diagnosed with Alzheimer's Disease in the early stage 2-6a according to the Functional Assessment Staging Test (In Appendix A)
- The mental capacity to give informed consent for research is made by an experienced geriatrician based on Appendix A.
- Aged 60-90 years old.
- Able to make informed consent under assistance, which is witnessed and signed by a family caregiver.
Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese UNiversity of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.